$STME
Stimcell Energetics Inc.

2023 Q4 Form 10-Q Financial Statement

#000139390523000350 Filed on October 16, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2023 Q2
Revenue $0.00 $0.00 $70.00
YoY Change -100.0% -100.0% -97.48%
Cost Of Revenue $0.00 $0.00 $550.00
YoY Change -100.0% -100.0% 1.85%
Gross Profit $0.00 $0.00 -$480.00
YoY Change -100.0% -100.0% -121.43%
Gross Profit Margin -685.71%
Selling, General & Admin $42.26K $50.75K $63.88K
YoY Change -61.64% -58.36% -38.35%
% of Gross Profit
Research & Development $301.00 $306.00 $420.00
YoY Change -98.66% -98.66% -99.2%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $42.56K $51.05K $64.30K
YoY Change -67.9% -64.72% -58.87%
Operating Profit -$42.56K -$51.05K -$64.78K
YoY Change -67.77% -64.79% -57.96%
Interest Expense $17.99K $25.90K -$14.61K
YoY Change 67.08% 167.52% 72.7%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$60.55K -$76.95K -$79.38K
YoY Change -57.6% -50.26% -51.17%
Income Tax
% Of Pretax Income
Net Earnings -$60.55K -$76.95K -$79.38K
YoY Change -57.6% -50.25% -51.17%
Net Earnings / Revenue -113400.0%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 62.92M shares 62.92M shares 62.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.62K $58.07K $98.30K
YoY Change 27.01% 503.64% 303.2%
Cash & Equivalents $22.62K $58.07K $98.30K
Short-Term Investments
Other Short-Term Assets $260.00 $4.252K $4.975K
YoY Change -95.81% -77.57% -70.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.88K $62.33K $103.3K
YoY Change -4.75% 118.09% 149.78%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.00 -$4.00 $0.00
YoY Change 50.0% 0.0%
TOTAL ASSETS
Total Short-Term Assets $22.88K $62.33K $103.3K
Total Long-Term Assets $3.00 -$4.00 $0.00
Total Assets $22.88K $62.33K $103.3K
YoY Change -4.74% 118.11% 149.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $648.2K $370.1K $408.3K
YoY Change 54.03% -15.08% -7.72%
Accrued Expenses $8.331K $42.48K $36.56K
YoY Change -73.4% 33.58% 26.61%
Deferred Revenue
YoY Change
Short-Term Debt $1.073M $1.056M $1.041M
YoY Change 33.27% 46.2% 58.26%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.548M $2.534M $2.489M
YoY Change 14.62% 18.77% 21.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.548M $2.534M $2.489M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.548M $2.534M $2.489M
YoY Change 14.62% 18.77% 21.38%
SHAREHOLDERS EQUITY
Retained Earnings -$10.29M -$10.23M -$10.15M
YoY Change 3.37% 4.25% 5.13%
Common Stock $62.92K $62.92K $62.92K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.525M -$2.471M -$2.385M
YoY Change
Total Liabilities & Shareholders Equity $22.88K $62.33K $103.3K
YoY Change -4.74% 118.11% 149.78%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$60.55K -$76.95K -$79.38K
YoY Change -57.6% -50.25% -51.17%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities -$35.33K -$40.36K -$25.62K
YoY Change -47.71% -46.66% -72.91%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $0.00 116.4K
YoY Change -100.0% -100.0% 32.1%
NET CHANGE
Cash From Operating Activities -35.33K -$40.36K -25.62K
Cash From Investing Activities
Cash From Financing Activities 0.000 $0.00 116.4K
Net Change In Cash -35.33K -$40.22K 90.75K
YoY Change -501.02% 172.5% -1498.31%
FREE CASH FLOW
Cash From Operating Activities -$35.33K -$40.36K -$25.62K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 dei Document Type
DocumentType
10-Q
CY2023Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q3 dei Document Period End Date
DocumentPeriodEndDate
2023-08-31
CY2023Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q3 dei Entity File Number
EntityFileNumber
000-54500
CY2023Q3 dei Entity Registrant Name
EntityRegistrantName
Cell MedX Corp.
CY2023Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
38-3939625
CY2023Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
123 W. Nye Ln
CY2023Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 446
CY2023Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Carson City
CY2023Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89706
CY2023Q3 dei City Area Code
CityAreaCode
844
CY2023Q3 dei Local Phone Number
LocalPhoneNumber
238-2692
CY2023Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q3 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62923063 shares
CY2023Q3 us-gaap Cash
Cash
58074 usd
CY2023Q2 us-gaap Cash
Cash
98295 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4252 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
4975 usd
CY2023Q3 us-gaap Assets
Assets
62326 usd
CY2023Q2 us-gaap Assets
Assets
103270 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
370094 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
408264 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42480 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36560 usd
CY2023Q3 fil Due To Related Party Current
DueToRelatedPartyCurrent
1064692 usd
CY2023Q2 fil Due To Related Party Current
DueToRelatedPartyCurrent
1003187 usd
CY2023Q3 fil Notes And Advances Due To Related Parties
NotesAndAdvancesDueToRelatedParties
887621 usd
CY2023Q2 fil Notes And Advances Due To Related Parties
NotesAndAdvancesDueToRelatedParties
875130 usd
CY2023Q3 us-gaap Notes Payable
NotesPayable
168804 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
165609 usd
CY2023Q3 us-gaap Liabilities
Liabilities
2533691 usd
CY2023Q2 us-gaap Liabilities
Liabilities
2488750 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62923063 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62923063 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
62923 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
62923 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7272701 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7272701 usd
CY2023Q3 fil Reserves
Reserves
366493 usd
CY2023Q2 fil Reserves
Reserves
366493 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10229730 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10152777 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
56248 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
65180 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2471365 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2385480 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62326 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103270 usd
CY2023Q3 fil Costs Of Goods Sold
CostsOfGoodsSold
0 usd
CY2022Q3 fil Costs Of Goods Sold
CostsOfGoodsSold
797 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
-281 usd
CY2023Q3 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
30001 usd
CY2022Q3 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
23665 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20747 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
98215 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
306 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22843 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
51054 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
144723 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
25899 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
9681 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-76953 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-154685 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8932 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
58994 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-85885 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-95691 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62923063 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62923063 shares
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2009031 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-154685 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
58994 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2104722 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2385480 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-76953 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-8932 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2471365 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-76953 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-154685 usd
CY2023Q3 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
17070 usd
CY2022Q3 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
9681 usd
CY2023Q3 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
8830 usd
CY2022Q3 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
0 usd
CY2023Q3 us-gaap Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
5407 usd
CY2022Q3 us-gaap Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
-37352 usd
CY2023Q3 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-750 usd
CY2022Q3 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2471 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1263 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1101 usd
CY2023Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5916 usd
CY2022Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2949 usd
CY2023Q3 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
10700 usd
CY2022Q3 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
30418 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40357 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75655 usd
CY2023Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
CY2022Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
61000 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61000 usd
CY2023Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
136 usd
CY2022Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
-105 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-40221 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14760 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98295 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24380 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58074 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9620 usd
CY2023Q2 fil Notes And Advances Due To Related Parties
NotesAndAdvancesDueToRelatedParties
875130 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10229730 usd
CY2023Q3 fil Due To Related Party Current
DueToRelatedPartyCurrent
1064692 usd
CY2023Q2 fil Due To Related Party Current
DueToRelatedPartyCurrent
1003187 usd
CY2023Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
30001 usd
CY2022Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
49181 usd
CY2023Q3 us-gaap Loans Payable
LoansPayable
808055 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
79566 usd
CY2023Q3 fil Notes And Advances Due To Related Parties
NotesAndAdvancesDueToRelatedParties
887621 usd
CY2023Q2 us-gaap Loans Payable
LoansPayable
809115 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
66015 usd
CY2023Q3 fil Notes Payable Related Parties Other
NotesPayableRelatedPartiesOther
39794 usd
CY2023Q2 fil Notes Payable Related Parties Other
NotesPayableRelatedPartiesOther
39715 usd
CY2023Q3 us-gaap Other Loans Payable
OtherLoansPayable
144058 usd
CY2023Q3 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
24746 usd
CY2023Q3 us-gaap Notes Payable
NotesPayable
168804 usd
CY2023Q2 us-gaap Other Loans Payable
OtherLoansPayable
143936 usd
CY2023Q2 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
21673 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
165609 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
-281 usd

Files In Submission

Name View Source Status
0001393905-23-000350-index-headers.html Edgar Link pending
0001393905-23-000350-index.html Edgar Link pending
0001393905-23-000350.txt Edgar Link pending
0001393905-23-000350-xbrl.zip Edgar Link pending
cmxc-20230831.htm Edgar Link pending
cmxc-20230831.xsd Edgar Link pending
cmxc_ex311.htm Edgar Link pending
cmxc_ex312.htm Edgar Link pending
cmxc_ex321.htm Edgar Link pending
cmxc_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
cmxc-20230831_cal.xml Edgar Link unprocessable
cmxc-20230831_lab.xml Edgar Link unprocessable
cmxc-20230831_def.xml Edgar Link unprocessable
cmxc-20230831_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cmxc-20230831_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending